The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis
Abstract
Background The incidence of hepatocellular carcinoma (HCC) has increased significantly in United States over the last few decades in parallel with the epidemic of nonalcoholic fatty liver disease (NAFLD). Limited data suggests that HCC could arise in steatotic liver without the presence of cirrhosis. The present study was conducted to characterize patients with NAFLD presenting with HCC in non-cirrhotic liver (NCL) compared to the NAFLD- HCC patients in association with cirrhotic liver (CL).Methods A retrospective analysis of all patients diagnosed with HCC and NAFLD diagnosis seen at our institution between 2003 and 2012 was done. The patients were characterized based on demographic and clinical variables as well as histological and tumor features. Comparisons between the NCL and CL groups were done using analysis of variance (ANOVA) or the non-parametric Kruskal-Wallis tests and Pearson's chi-square tests or Fisher's Exact tests as appropriate. P value of <0.05 was considered statistically significant.Results Thirty-six patients with NAFLD and HCC in NCL (HCC-NCL group) were identified and compared to 47 patients with NAFLD-HCC and Liver Cirrhosis (HCC-LC group). Liver fibrosis was not present in 55.9 % of patients in the HCC-NCL group (F0), stage 1 was present in 17.6 %, stage 2 in 8.8 % and stage 3 in 17.6 %. Lobular inflammation was present in 63.6 % of non-cirrhotic patients. Patients in the HCC-NCL were older (67.5 ± 12.3 vs. 62.7 ± 8.1 years), and less likely to be obese (52 % vs. 83 %) or have type 2 diabetes (38 % vs. 83 %), with p value <0.05 for all. More importantly, compared with the HCC-CL group, those in the HCC-NCL group were more likely to present with a single nodule (80.6 % vs. 52.2 %), larger nodule size (>5 cm) (77.8 % vs. 10.6 %), and receive hepatic resection as the modality of HCC treatment (66.7 % vs. 17 %); and were less likely to receive loco-regional therapy (22.3 % vs. 61.7 %) or orthotopic liver transplantation (OLT) (0 % vs. 72.3 %), with p value <0.001 for all. Furthermore, 86 % of patients without cirrhosis had HCC recurrence compared to only 14 % in patients with cirrhosis (p < 0.001). Unadjusted analysis indicates that non-cirrhotics had worse survival with mortality rate of 47 % vs. 28 % in CL group (p = 0.03); however this difference in survival between two groups was not significant after adjusting for age or OLT (p > 0.05).Conclusion Patients with HCC in the absence of liver cirrhosis are more likely to present at an older age with larger tumor and have higher rates of tumor recurrence. Studies to assess the cost-effectiveness of HCC surveillance in this group should be conducted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective analysis of individuals with MASLD who were diagnosed with HCC between 2003 and 2012, those with HCC on a non-cirrhotic liver more frequently had a larger nodule size and/or a greater rate of HCC recurrence than those with cirrhosis. 235”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [235]
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El‐Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,484
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182
Waist circumference as a measure for indicating need for weight management
Lean, M. E. J., Han, T. S., & Morrison, C. E. (1995) · BMJ · doi:10.1136/bmj.311.6998.158 · Cited by 1,869
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,695
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,349
Cited by
Sorted by citations
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,251
Eslam, M., Sarin, S. K., Wong, V. W., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M., Shiha, G. E.-S., Yilmaz, Y. N., Gani, R. A., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 860
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Foerster, F., Gairing, S. J., Müller, L., & Galle, P. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 285
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Ahn, S. B., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 276
NAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2022) · Hepatology · doi:10.1002/hep.32542 · Cited by 270
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Huang, T. (., Behary, J., & Zekry, A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14709 · Cited by 227
Orci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
Younossi, Z. M., & Henry, L. L. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100305 · Cited by 226
Cholankeril, G. T., Patel, R., Khurana, S., & Satapathy, S. K. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i11.533 · Cited by 185
Should we undertake surveillance for HCC in patients with NAFLD?
Younes, R., & Bugianesi, E. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.006 · Cited by 165
Mantovani, A., & Targher, G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.04.41 · Cited by 170
Alkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668374 · Cited by 162
Self-citationHu, B., Lin, J., Yang, X., & Sang, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12772 · Cited by 149
Gawrieh, S., Dakhoul, L., Miller, E., Scanga, A., deLemos, A., Kettler, C., Burney, H., Liu, H., Abu-Sbeih, H., Chalasani, N., et al. (2019) · Alimentary Pharmacology and Therapeutics · doi:10.1111/apt.15464 · Cited by 118
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126
Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment
Zhang, P., Chen, Z., Kuang, H., Liu, T., Zhu, J., Zhou, L., Wang, Q., Xiong, X., Meng, Z., Qiu, X., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.010 · Cited by 105
Younossi, Z. M., Noureddin, M., Bernstein, D., Kwo, P. Y., Russo, M. W., Shiffman, M. L., Younes, Z. H., & Abdelmalek, M. F. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001054 · Cited by 104
Emerging role of aging in the progression of NAFLD to HCC
He, Y., Su, Y., Duan, C., Wang, S., He, W. G., Zhang, Y., An, X., & He, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101833 · Cited by 100
Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis
Bengtsson, B., Stål, P., Wahlin, S., Björkström, N., & Hagström, H. (2019) · Liver international (Print) · doi:10.1111/liv.14087 · Cited by 84
Sobolewski, C., Abegg, D., Berthou, F., Dolicka, D., Calo, N., Sempoux, C. L., Fournier, M., Maeder, C., Ay, A., Clavien, P., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319019 · Cited by 99
Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023) · Biomedicines · doi:10.3390/biomedicines11020468 · Cited by 94
Chrysavgis, L., Giannakodimos, I., Diamantopoulou, P., & Cholongitas, Ε. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i3.310 · Cited by 84
Pοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 84
Han, M. A. T., Vipani, A., Noureddin, N., Ramirez, K., GORNBEIN, J. A., Saouaf, R., Baniesh, N., Cummings-John, O. D., Okubote, T. C., Setiawan, V. W., et al. (2020) · Liver International · doi:10.1111/liv.14593 · Cited by 75
Self-citationDeregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
Kaffe, E., Magkrioti, C., & Aidinis, V. (2019) · Cancers · doi:10.3390/cancers11111626 · Cited by 75
Pinyopornpanish, K., Khoudari, G., Saleh, M. A., Angkurawaranon, C., Pinyopornpanish, K., Mansoor, E., Dasarathy, S., & McCullough, A. J. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01978-0 · Cited by 75
Díaz, L. A., Fuentes–López, E., Ayares, G., Idalsoaga, F. J., Arnold, J., Márquez‐Lomas, A., Ramírez, C., Medel, M. P., Viñuela, F., Lacalle, L., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00008-5 · Cited by 73
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease
Bertot, L. C., & Adams, L. A. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1549989 · Cited by 68
Wong, S.-W., Ting, Y.-W., & Chan, W. (2018) · JGH Open · doi:10.1002/jgh3.12070 · Cited by 58
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
Ito, T., & Nguyen, M. H. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347959 · Cited by 65
Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis
Cerreto, M., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2021) · Nutrients · doi:10.3390/nu13082649 · Cited by 58
Lipid droplets are intracellular mechanical stressors that impair hepatocyte function
Loneker, A. E., Alisafaei, F., Kant, A., Li, D., Janmey, P. A., Shenoy, V. B., & Wells, R. G. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216811120 · Cited by 54
Schaefer, E. A. K., Wu, W. W., Mark, C., Yang, A., DiGiacomo, E., Carlton‐Smith, C., Salloum, S., Brisac, C., Lin, W., Corey, K. E., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1045 · Cited by 56
Torres, M. C. P., Bodini, G., Furnari, M., Marabotto, E., Zentilin, P., Strazzabosco, M., & Giannini, E. G. (2020) · Cancers · doi:10.3390/cancers12061422 · Cited by 54
Pal, P., Palui, R., & Ray, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1584 · Cited by 51
Consenso mexicano de la enfermedad por hígado graso no alcohólico
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.11.007 · Cited by 52
Caddeo, A. M., Serra, M., Sedda, F., Bacci, A., Manera, C., Rapposelli, S., Columbano, A., Perra, A., & Kowalik, M. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1127517 · Cited by 43
Hughey, C. C., Puchalska, P., & Crawford, P. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159209 · Cited by 45
NAFLD Related-HCC: The Relationship with Metabolic Disorders
Zhang, X. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_5 · Cited by 39
Farah, M., Anugwom, C. M., Ferrer, J. D., Baca, E. L., de Mattos, Â. Z., Possebon, J. P. P., Arrese, M. A., Prieto, J. E., Balderramo, D. C., Carrera, E., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100876 · Cited by 40
Ritchie, M. M., Hanouneh, I. A., Noureddin, M., Rolph, T., & Alkhouri, N. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1718104 · Cited by 37
Self-citationPCAF fine‐tunes hepatic metabolic syndrome, inflammatory disease, and cancer
Wang, T., Yao, W., Shao, Y., Zheng, R., & Huang, F. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13877 · Cited by 36
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer, H., Shibolet, O., & Deutsch, L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3929 · Cited by 36
The Mexican consensus on nonalcoholic fatty liver disease
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.02.003 · Cited by 35
Ahmad, M. I., Khan, M. U., Kodali, S., Shetty, A., Bell, S. M., & Victor, D. W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s344559 · Cited by 36
Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis
Younossi, Z. M., & Henry, L. L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.010 · Cited by 35
Schotten, C., Bechmann, L. P., Manka, P. P., Theysohn, J. M., Dechêne, A., Fouly, A. E., Barbato, F., Neumann, U., Radünz, S., Sydor, S., et al. (2019) · Liver Cancer · doi:10.1159/000501484 · Cited by 33
Eshraghian, A., Nikeghbalian, S., Geramizadeh, B., & Malek‐Hosseini, S. A. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617707863 · Cited by 32
Chin, K. M., Prieto, M., Cheong, C., di Martino, M., Ielpo, B., Goh, B., & Koh, Y. (2021) · HPB · doi:10.1016/j.hpb.2021.01.009 · Cited by 30
Hepatocellular carcinoma in the non-cirrhotic liver
Dong, Y., Wang, W.-P., Lee, W. J., Meloni, M. F., Clevert, D.-A., Chammas, M. C., Tannapfel, A., Forgione, A., Piscaglia, F., & Dietrich, C. F. (2021) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-211309 · Cited by 32
Dong, Y., Wang, W.-P., Lee, W., Meloni, M., Clevert, D., Chammas, M., Tannapfel, A., Forgione, A., Piscaglia, F., & Dietrich, C. (2022) · Ultrasound in Medicine and Biology · doi:10.1016/j.ultrasmedbio.2022.05.005 · Cited by 30
Gómez-Quiroz, L. E., Seo, D., Lee, Y., Kitade, M., Gaiser, T., Gillen, M. C., Lee, S. B., Gutiérrez‐Ruíz, M. C., Conner, E. A., Factor, V. M., et al. (2016) · Toxicology · doi:10.1016/j.tox.2016.07.004 · Cited by 31
Iso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis, inflammation, and fibrosis
Mahli, A., Koch, A., Fresse, K., Schiergens, T. S., Thasler, W. E., Schönberger, C., Bergheim, I., Bosserhoff, A., & Hellerbrand, C. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0112-x · Cited by 30
Shi, J., Ren, M., She, X., Zhang, Z., Zhao, Y. X., Han, Y., Lü, D., & Lyu, L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.028 · Cited by 30
Chen, V. L., Yeh, M., Yang, J. D., Leong, J., Huang, D. Q., Toyoda, H., Chen, Y., Guy, J. E., Maeda, M., Tsai, P., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1606 · Cited by 29
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Tovo, C. V., de Mattos, Â. Z., Coral, G. P., SARTORI, G. D. P., Nogueira, L. V., Both, G. T., Villela‐Nogueira, C. A., & de Mattos, Â. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.343 · Cited by 35
Hang, W., Shu, H., Zheng, W., Liu, J., Jin, Z., Shi, Z., Chen, C., & Wang, D. W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.636204 · Cited by 29
Antwi, S. O., Craver, E. C., Nartey, Y. A., Sartorius, K., & Patel, T. C. (2022) · Cancers · doi:10.3390/cancers14246234 · Cited by 30
Ziamanesh, F., Mohammadi, M., Ebrahimpour, S., Tabatabaei‐Malazy, O., Mosallanejad, A., & Larijani, B. A. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01293-3 · Cited by 28
Ding, B., Lou, W., Liu, J., Li, R., Chen, J., & Fan, W. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0901-3 · Cited by 28
Rejuvenation: Turning Back Time by Enhancing CISD2
Yeh, C., Shen, Z., Lin, C.-C., Lu, C.-K., & Tsai, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214014 · Cited by 29
Yilma, M., Saxena, V., & Mehta, N. J. (2022) · Current Gastroenterology Reports · doi:10.1007/s11894-022-00835-8 · Cited by 24
Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?
Lange, N. F., & Dufour, J. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05515-8 · Cited by 20
The Future of Nonalcoholic Fatty Liver Disease Treatment
Mazhar, K. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.08.005 · Cited by 24
Mei, Y., You, Y., Xia, J., Gong, J., & Wang, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000492254 · Cited by 21
Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma
Castellana, M., Donghia, R., Lampignano, L., Castellana, F., Zupo, R., Sardone, R., Pergola, G. D., & Giannelli, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204638 · Cited by 20
Wang, K., Chen, F., Wang, J., & Liu, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.025 · Cited by 23
The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
Kogiso, T., & Tokushige, K. (2021) · Cancers · doi:10.3390/cancers13030516 · Cited by 20
Kugelmas, M., Noureddin, M., Gunn, N., Brown, K., Younossi, Z. M., Abdelmalek, M. F., & Alkhouri, N. (2023) · Liver International · doi:10.1111/liv.15555 · Cited by 18
Self-citationMetabolic factors affecting hepatocellular carcinoma in steatohepatitis
Zarrinpar, A., Faltermeier, C. M., Agopian, V. G., Naini, B. V., Harlander‐Locke, M. P., Kaldas, F. M., Farmer, D. G., & Busuttil, R. W. (2018) · Liver International · doi:10.1111/liv.14002 · Cited by 19
Anastasopoulos, N.-A., Lianos, G. D., Tatsi, V., Karampa, A. D., GOUSSIA, A. C., & Glantzounis, G. K. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1802244 · Cited by 18
NAFLD as a risk factor for HCC: new rules of engagement?
Masuzaki, R., Karp, S. J., & Omata, M. (2016) · Hepatology International · doi:10.1007/s12072-016-9731-8 · Cited by 18
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 18
Dong, K., Zhang, Y., Huang, J., Xia, S.-S., & Yang, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.10 · Cited by 16
Deng, L. X., & Mehta, N. J. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06550-6 · Cited by 18
Liu, R., Qian, M., & Cui, Y. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155665 · Cited by 17
Billeter, A. T., Müller, P. C., Albrecht, T., Roessler, S. K., Löffler, M., Murtha-Lemekhova, A., Mehrabi, A., Müller-Stich, B. P., & Hoffmann, K. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04628-0 · Cited by 16
Cespiati, A., Cinque, F., Meroni, M., Lombardi, R., Dongiovanni, P., & Fracanzani, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11020586 · Cited by 17
Liu, Y., Li, H., Ye, N., Luo, C.-J., Hu, Y.-Y., Wu, H., & Gong, J. (2019) · Medical Science Monitor · doi:10.12659/msm.915722 · Cited by 15
Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma
Makita, Y., Murata, S., Katou, Y., Kikuchi, K., Uejima, H., Teratani, M., Hoashi, Y., Kenjo, E., Matsumoto, S., Nogami, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.088 · Cited by 15
Alrasheed, M. A., Guo, J. J., Lin, A. C., Wigle, P. R., Hardee, A. M., & Hincapie, A. L. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03090-6 · Cited by 14
New insights on hepatocellular carcinoma: epidemiology and clinical aspects
Puoti, C. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.67 · Cited by 14
Li, T., Zhang, G.-H., Wang, L.-L., Li, S., Xu, X.-P., & Gao, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00225 · Cited by 9
Gopalakrishna, H., Fashanu, O. E., Nair, G. B., & Ravendhran, N. (2022) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-22-1 · Cited by 12
Jin, J., Cheng, K., Chen, M., Liang, H., & Zhang, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 13
Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis
Onzi, G., Moretti, F., Balbinot, S. S., Balbinot, R. Â., & Soldera, J. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2018.114 · Cited by 11
Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
Inayat, F., Rahman, Z. U., & Hurairah, A. (2016) · Cureus · doi:10.7759/cureus.754 · Cited by 11
Xiong, G., Huang, C., Zou, Y., Tao, Z., Zou, J., & Huang, J. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/4912961 · Cited by 10
Suwa, K., Yamaguchi, T., Yoshida, K., Murata, M., Ichimura‐Shimizu, M., Tsuneyama, K., Seki, T., & Okazaki, K. (2020) · Cancers · doi:10.3390/cancers12020286 · Cited by 10
Alomari, M., Rashid, M. U., Chadalavada, P. N., Ragheb, J. G., Zafar, H., Suarez, Z. K., Khazaaleh, S., Gonzalez, A. J., & Castro, F. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.477 · Cited by 11
Farrell, A., Ryan, M. C., & Howell, J. A. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2019.019 · Cited by 9
HOMA-IR index in non-diabetic patient, a reliable method for early diagnosis of liver steatosis.
Motamed, B., Vajargah, M. K., Kalantari, S., & Shafaghi, A. (2022) · PubMed Central · doi:10.22088/cjim.13.3.519 · Cited by 10
Xu, K., Wu, T., Li, X., Zhang, X., Liu, X., Ma, S., Dong, W., Yang, J., Liu, Y., Fang, W., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156267 · Cited by 9
Liu, Y. (2025) · Liver Cancer · doi:10.1159/000550163 · Cited by 12
Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma
Fetzer, D. T., Rodgers, S. K., Seow, J. H.-S., Dawkins, A. A., Joshi, G., Gabriel, H. A., & Kamaya, A. (2019) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2019.01.004 · Cited by 9
Noureddin, N., Han, M. A. T., Alkhouri, N., & Noureddin, M. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00505-1 · Cited by 8
Self-citation
Metadata
- Authors
- Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., Hanouneh, I. A., Alhaddad, R., & Alkhouri, N.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Alkhouri, Naim
- Venue
- Hepatology International
- Published
- 2015-11-11
- Volume
- 10
- Issue
- 4
- Pages
- 632-639
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W2117454090
- Cited by
- 166
- References
- 35
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 8 · 2023: 18 · 2022: 24 · 2021: 24 · 2020: 23 · 2019: 21 · 2018: 11 · 2017: 9 · 2016: 7
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Hepatology International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatocellular carcinoma, non-alcoholic fatty liver disease, non-cirrhotic liver, liver cirrhosis, liver fibrosis, lobular inflammation, hepatectomy, liver transplantation, survival outcomes, prognostic factors, obesity, type 2 diabetes
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review